Replies to post #108467 on Biotech Values

[go seek]

Yep, its a 'read between the lines' article. Perhaps the WSJ followup will carry the real story which is well-stated in your post.

That is:
MNTA (An American company) has raised the bar in the quality of generic that is possible to be created...

[DewDiligence]

MNTA/TEVA—If any political capital is going to be expended on this matter, it will likely be expended in MNTA’s favor, IMO.

Everyone in Washington wants lower healthcare costs, and generic drugs help lower healthcare costs. MNTA—the one company with a proven ability to bring complex generic drugs to the US market—would thus seem to have an ample reservoir of goodwill on Capital Hill and in the White House.

Would Congress pressure the FDA to take some kind of action that undermined MNTA’s commercial success and thereby made it harder for other complex generic drugs to reach US consumers? I just don’t see it.

p.s. Has anyone heard from the Sanford Bernstein analysts lately? :- )